Clinical Trial: Intravitreal Injections of Melphalan for Retinoblastoma

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: Intravitreal Injections of Melphalan for Retinoblastoma

Brief Summary:

Retinoblastoma treatment has become more and more focused in the last years. New treatments developed by Dr. Kaneko from Japan in 1995 are now being tested in clinical trials.

Intra-arterial chemotherapy with Melphalan has shown success in some patients but with limited response when there is marked vitreal seeding. For these cases Intravitreal injections of Melphalan have been successful in Japan.

In this study the same chemotherapy (melphalan) will be administered intravitreally (directly through the eye wall) and the response (short and long term) will be monitored.


Detailed Summary: Intravitreal injections of Melphalan will be given to cases unresponsive to chemotherapy or with vitreal seeding of the disease.
Sponsor: Hadassah Medical Organization

Current Primary Outcome: treatment response [ Time Frame: 1 year ]

short term response to treatment and long term complications


Original Primary Outcome: Same as current

Current Secondary Outcome: complications [ Time Frame: 1 year ]

short and long term complications


Original Secondary Outcome: Same as current

Information By: Hadassah Medical Organization

Dates:
Date Received: March 1, 2012
Date Started: March 2012
Date Completion:
Last Updated: August 19, 2015
Last Verified: March 2012